Hypoport’s Europace Volumes Flat at €38.3bn as Iran-Induced Rush Fades in Second Quarter

The geopolitical shockwaves from the Iran conflict sent a transient surge through Germany’s mortgage market early this year, pulling forward billions in financing decisions and creating a starkly split first half for Hypoport. The company’s flagship platform, Europace, processed €38.31 billion in transaction volume during the six months to June 2026 — virtually unchanged from the €38.35 billion recorded a year earlier. Yet the aggregate stability masks a sharp intra-year swing: the first quarter delivered an extraordinary €20.27 billion as borrowers rushed to lock in terms before an Iran-driven spike in interest rates, followed by a second-quarter comedown to €18.04 billion. Against the prior year’s second quarter of €17.97 billion, that Q2 reading actually registered a fractional gain, but the underlying demand pulse has clearly softened.

A deeper look at the product mix reveals where the market is headed. The Sparkassen-focused platform Finmas grew 13% to €6.61 billion, while Genopace, the Genossenschaftsbanken channel, added 7% to €10.47 billion. Both groups strengthened their market share at the expense of private banks, according to Hypoport. The Bauspar (home loan savings) segment contracted 16% to €2.57 billion, while installment loans jumped 11% to €4.04 billion. The Value AG subsidy platform notched an 18% increase to €21.18 billion, and Dr. Klein Wowi Digital — targeting institutional residential property managers — boosted its managed unit count by around 29% to 734,000, even though the associated credit volume rose only modestly. The REM Capital division posted an 8% half-year gain to €1.19 billion, but collapsed 54% in the second quarter alone, signaling that lower-margin subsidy programs are increasingly weighing on growth. Neubau (new construction) saw the strongest percentage expansion, albeit from a tiny base, while energy-efficiency renovations remain below levels that Hypoport considers necessary.

Hypoport management reaffirmed its full-year guidance alongside the half-year update. Gross profit is expected to reach at least €280 million, with operating earnings projected between €40 million and €55 million. The solid Q1 — where gross profit rose 8% to €71 million and the EBIT margin improved from 13% to 17% — underpins that outlook. CEO Ronald Slabke stressed the company’s continued market share gains in a difficult environment and pointed to increased deployment of artificial intelligence to drive efficiency and defend those gains. On the shareholder front, the June annual general meeting authorized the use of treasury shares for the “Hypoport-Bonus” employee incentive program, a tool for retention with no immediate operational signal.

Should investors sell immediately? Or is it worth buying Hypoport?

The analyst community has recalibrated expectations sharply. In early July, Warburg Research lowered its price target from €291 to €134 — a dramatic cut following an analyst change to Andreas Pläsier — while maintaining a “Buy” rating. The revision underscores how far the earnings outlook has been scaled back since the stock hit its highs a year ago, even if the fundamental bullish stance persists.

Shares have begun to creep off the floor. Currently trading around €88.70, the stock has risen 6.4% over the past seven trading days and roughly 12.4% over the last 30 days, extending a recovery from the 52-week low struck in late March. Yet the title remains 11.5% below its 200-day moving average, suggesting the base-building process is far from complete. The company’s market capitalization stands at approximately €567 million.

Investors are now awaiting the full half-year report, due August 10, which should offer clearer clues on whether the Europace stabilization can last through the second half or whether the first-quarter pull-forward effects have exhausted themselves. The next regular quarterly update is scheduled for November 9.

Ad

Hypoport Stock: New Analysis - 17 July

Fresh Hypoport information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Hypoport analysis...

en | DE0005493365 | HYPOPORT’S | boerse | 69783409 |